Featuring an interview with Dr Aaron Lisberg, including the following topics:

• Prevention and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (Dato-DXd) (0:00)
  • Rugo H et al. US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan. Support Care Cancer 2025;33(9):756. Abstract
  • Lisberg A et al. Datopotamab deruxtecan-associated select adverse events: Clinical practices and institutional protocols on prophylaxis, monitoring, and management. Oncologist 2025;[Online ahead of print]. Abstract
  • Meric-Bernstam F et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Oncologist 2025;30(3). Abstract
• Novel Strategies Combining Dato-DXd with Osimertinib (10:44)
  • Lu S et al. TROPION-Lung14: A phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC). ASCO 2025;Abstract TPS8647.
  • Nadal E et al. TROPION-Lung15: A phase III study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib. ELCC 2025;Abstract 124TiP.
• Intracranial Activity Observed with TROP2-Targeting Antibody-Drug Conjugates (15:14)
  • Felip E et al. Brain metastases and actionable genetic alterations with sacituzumab govitecan versus docetaxel in metastatic non-small cell lung cancer: Subgroups of the phase III EVOKE-01 trial. ELCC 2025;Abstract 13P.
  • Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593.
  • Pons-Tostivint E et al. Intracranial efficacy of datopotamab deruxtecan (Dato- DXd) in patients with advanced/metastatic NSCLC in TROPION-Lung01. WCLC 2025;Abstract OA10.01.

CME information and select publications

Featuring perspectives from Dr Kathleen N Moore and Dr Matthew A Powell, including the following topics:

• Introduction: A Pan-tumor Perspective on Microsatellite Instability (MSI)-High Disease — Immunotherapy for Localized Disease (0:00)
• Case: A woman in her early 60s with mismatch repair-deficient metastatic endometrial cancer (EC) and multiple positive metastases — Shachar Peles, MD (8:18)
• Case: A woman in her mid 60s with recurrent EC and a BRCA mutation — Stephen "Fred" Divers, MD (12:17)
• Data Review: Immune Checkpoint Inhibitors (15:26)
• Case: A woman in her early 30s with Stage I mismatch repair-proficient EC and multiple pulmonary metastases after receiving fertility treatments — Kellie E Schneider, MD (28:22)
• Case: A woman in her early 80s with EC and high blood pressure — Syed F Zafar, MD (34:24)
• Case: A postmenopausal woman in her late 60s with recurrent HER2-positive EC and unresectable carcinomatosis — Lyndsay J Willmott, MD (38:18)
• Case: A woman in her late 60s with EC and pericarditis — Karim ElSahwi, MD (44:28)
• Data Review: Novel Antibody-Drug Conjugates (51:38)
• Case: A woman in her early 70s with metastatic MSI-stable, HER2-negative EC with PI3 kinase and FGFR mutations wants to avoid treatment with chemotherapy — Victoria Giffi, MD (55:01)

CME information and select publications

Featuring an interview with Prof Patrick Neven, including the following topics:

• Emergence of ESR1 mutations in ER-positive, HER2-negative breast cancer (0:00)
• Observed toxicity profile of oral selective estrogen receptor degraders (SERDs) (3:57)
• Emerging data with novel oral SERD combinations (6:31)
• Challenges for a general medical oncologist in breast cancer (8:41)
• Sequencing and selection of therapies in ER-positive, HER2-negative breast cancer (12:16)
• Evaluating the strategy of switching to an oral SERD during first-line endocrine therapy upon "molecular progression" (23:16)

CME information and select publications